- Home
- GRDX vs CLDI Comparison
GRDX vs CLDI Comparison
Compare GRDX & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.91
HOLD
Current Price
$0.89
Company Overview
Basic Information| Metric | GRDX | CLDI |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GRDX | CLDI |
|---|---|---|
| Price | $2.91 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 139.5K | 90.7K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $0.84 |
| 52 Week High | $5.30 | $19.20 |
Technical Indicators
Market Signals| Indicator | GRDX | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical Comparison GRDX
CLDI
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.